IRC-083927

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406511

CAS#: 955082-09-4

Description: IRC-083927 is novel and potent microtubule inhibitor with potential anticancer activity. IRC-083927 inhibits the tubulin polymerization by a binding to the colchicine site. IRC-083927 inhibits in vitro cell growth of human cancer cell lines in the low nanomolar range. More interesting, it remains highly active against cell lines resistant to microtubule-interacting agents (taxanes, Vinca alkaloids, or epothilones). Chronic oral treatment with IRC-083927 (5 mg/kg) inhibits the growth of two human tumor xenografts in nude mice (C33-A, human cervical cancer and MDA-MB-231, human hormone-independent breast cancer). Together, the antitumor effects induced by IRC-083927 on tumor models resistant to tubulin agents support further investigations to fully evaluate its potential for the treatment of advanced cancers, particularly those resistant to current clinically available drugs.


Chemical Structure

img
IRC-083927
CAS# 955082-09-4

Theoretical Analysis

MedKoo Cat#: 406511
Name: IRC-083927
CAS#: 955082-09-4
Chemical Formula: C22H19FN4O4S
Exact Mass: 454.1111
Molecular Weight: 454.47
Elemental Analysis: C, 58.14; H, 4.21; F, 4.18; N, 12.33; O, 14.08; S, 7.06

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Synonym: IRC083927; IRC 083927; IRC-083927.

IUPAC/Chemical Name: Sulfamide, N-​[2-​fluoro-​4-​[4-​[2-​(phenoxymethyl)​-​1H-​imidazol-​5-​yl]​phenoxy]​phenyl]​-​, hydrochloride.

InChi Key: WDKXZCKBBNZPLY-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H19FN4O4S.ClH/c23-19-12-18(10-11-20(19)27-32(24,28)29)31-17-8-6-15(7-9-17)21-13-25-22(26-21)14-30-16-4-2-1-3-5-16;/h1-13,27H,14H2,(H,25,26)(H2,24,28,29);1H

SMILES Code: O=S(N)(NC1=CC=C(OC2=CC=C(C3=CN=C(COC4=CC=CC=C4)N3)C=C2)C=C1F)=O.[H]Cl

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 454.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Chan D. Medicinal Chemistry - XXIst International Symposium. IDrugs. 2010 Nov;13(11):749-52. PubMed PMID: 21046517.

2: Liberatore AM, Coulomb H, Pons D, Dutruel O, Kasprzyk PG, Carlson M, Nelson AS, Newman SP, Stengel C, Auvray P, Hesry V, Foll B, Narboux N, Morlais D, Le Moing M, Bernetiere S, Dellile R, Camara J, Ferrandis E, Bigg DC, Prévost GP. IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents. Mol Cancer Ther. 2008 Aug;7(8):2426-34. doi: 10.1158/1535-7163.MCT-08-0208. Erratum in: Mol Cancer Ther. 2009 Jan;8(1):274. PubMed PMID: 18723488.

IRC-083927

10.0mg / Not available


Additional Information